Technical Service Agreement (TSA)

Overview

Frederick National Laboratory for Cancer Research scientists provide services and solutions to collaborators through the Technical Services Program, whose portfolio includes more than 200 collaborations with more than 80 partners. The Frederick National Laboratory's unique offerings cover HIV and SIV services; KRAS/p53 mouse models and cell lines for PDAC and NSCLC with assessment of drug toxicity, efficacy, tolerance, survival, and pharmacokinetics; 1,501 mouse embryonic cell lines with most known mouse miRNAs; HLA genotyping; expression profiling for human B-cell lymphoma on the NanoString platform.

For more information on our Technical Services, contact:

Victoria Brun
Partnership Development Office
Victoria.Brun@nih.gov
(301) 846-1997

Nanomedicines and Nanoformulation

Service Description Contact FNLCR Technical Service Number

Nanomedicine Drug Release Study in Human Plasma Using Stable Isotope Tracer Ultrafiltration Assay (SITUA)

  • Bioanalytical sample analysis to calculate concentrations of (a) encapsulated, (b) unencapsulated, free-unbound, and (c) unencapsulated, protein-bound drug
  • Consultation on methods, results, and data interpretation. Additional information.

Stephan Stern,
sternstephan@mail.nih.gov

NCL-01

Nanomedicine Pharmacokinetics in Rats Evaluated by SITUA

  • Conducted at various timepoints and processed using the SITUA method
  • Bioanalytical sample analysis to calculate concentrations of a) encapsulated, (b) unencapsulated, free-unbound, and (c) unencapsulated, protein-bound drug
  • Evaluated using noncompartmental PK
  • Consultation on methods, results, and data interpretation. Additional information.

Stephan Stern,
sternstephan@mail.nih.gov

NCL-02

 

HIV/SIV Services

Service

Description

Contact

FNLCR Technical Service Number

qPCR SIV Viral Load Analysis

  • qPCR and qRT-PCR for SIV replication and expression. 
  • Coverage of isolates used most commonly in SIV experimental studies
  • Plasma analyzed at standard (15 copies/mL) or ultrasensitive (1.6 copies/mL) detection levels. Additional information.

Jeff Lifson, M.D.,
lifsonj@mail.nih.gov

 

ACVP-02
ACVP-13
Novel CD4 + T Cell Specific Immunohistochemistry Detection and Analysis utilizing masking of not-T cell CD4 in fixed tissues from virally infected and uninfected specimens
  • Slides stained for CD4 & CD68/CD163 markers by immunohistochemistry for macrophages/dendritic cells. 
  • Quantitative image analysis for CD4+ T cells. Additional information.

Claire Deleage, Ph.D,
claire.deleage@nih.gov

ACVP-03

Hybrid RT/Digital SIV qPCR Viral Load Analysis

  • Samples (cell pellets or tissue) prepared as necessary.
  • Full protocol for both RNA and DNA determinations including cell equivalents. Additional information.

Jeff Lifson, M.D.,
lifsonj@mail.nih.gov

 

ACVP-06
ACVP-08

Quantitative Assessment of Lymphoid Tissue Fibrosis in Formalin Fixed Tissue
  • Automated immunohistochemistry of Collagen I, Collagen II, and Fibronectin in formalin-fixed tissue. 
  • Quantitative image analysis included. Additional information.

Claire Deleage, Ph.D.,
claire.deleage@nih.gov

ACVP-11
Quantitative Assessment of HIV/SIV Viral DNA in Laser Capture Microdissected (LCM) CD4+ T cell and/or Macrophage Populations from Formalin-Fixed Tissue Specimens
  • Up to 3,000 individual CD4+ T cells or macrophages captured by LCM in formalin-fixed tissue samples.
  • Standard qPCR on captured cell population. Additional information.
Claire Deleage, Ph.D.,
claire.deleage@nih.gov
ACVP-12

HIV/SIV Single Genome Amplification/ cDNA Synthesis

  • Viral DNA/RNA extraction from cell-free or cell-associated samples
  • Single copy PCR amplification of entire viral gene of interest
  • Comprehensive sequence analysis included. Additional information.

Brandon Keele, Ph.D.,
keelebf@mail.nih.gov

 

ACVP-05
Lineage-specific Next Gen Multiplex In Situ Hybridization for HIV/SIV RNA and DNA
  • Fixed tissue samples analyzed with lineage-specific riboprobes
  • Assay automation for consistency
  • Quantitative image analysis included. Additional information.
Claire Deleage, Ph.D.,
claire.deleage@nih.gov
ACVP-14 A-E
Next-Generation Sequence Analysis of Barcoded SIV/SHIV/HIV from DNA or RNA Containing Material
  • PCR and next-generation sequence analysis of a barcoded virus using Illumina sequencing on a MiSeq instrument
  • Determination of the number, proportion, and unique sequence of each barcode. Additional information

Christine Fennessey, Ph.D.,
christine.fennessey@nih.gov

ACVP-15

 

Laboratory Animal Services

Service

Description

Contact

FNLCR Technical Service Number

Use of Mouse Embryonic Stem Cells Expressing miRNAs

  • Tetracycline-inducible novel mouse embryonic cell lines
  • 1,501 cell lines available, with most known mouse miRNAs. Additional information.

Debra Fitzgerald,
fitzgeraldd@mail.nih.gov

 

LASP-01

In Vitro Cell Cytotoxicity Evaluation

  • Dose-response to candidate compounds measured at 6 escalating concentrations.
  • Available in Kras/p53 PDAC or Kras/p53 NSCLC derived cells. Additional information.

Serguei Kozlov, Ph.D.,
kozlovse@mail.nih.gov

LASP-02
LASP-08

Pharmacokinetic Evaluation in Kras/p53 PDAC Mice

  • Five time points plus vehicle control
  • Collection of plasma/serum and multiple tissue samples for PK
  • Detailed pathology assessment of H&E-stained tissues at endpoint. Additional information.

Serguei Kozlov, Ph.D.,
kozlovse@mail.nih.gov

LASP-03

Tolerance Evaluation of Experimental Compound in Kras/p53 PDAC Mice

  • One or two dosing arms plus a vehicle control arm
  • Includes full toxicology report
  • Includes cryopreserved tissues and blood plasma. Additional information.

Serguei Kozlov, Ph.D.,
kozlovse@mail.nih.gov

 

LASP-04

Time Course Assessment of Tumor Response to Therapeutics

  • Four arm study. 
  • Tumor monitoring by longitudinal imaging (MRI or ultrasound)
  • Includes biomarker evaluation, cryopreserved tissues and plasma
  • Available in Kras/p53 PDAC or Kras/p53 NSCLC mice. Additional information.

Serguei Kozlov, Ph.D.,
kozlovse@mail.nih.gov

LASP-05
LASP-09

Assessment of Drug Efficacy in a Survival Study

  • Available in three, four, or five arm study format. 
  • Includes cryopreserved tissues and blood plasma. 
  • Includes quantitative assessment of up to five informative biomarkers by immunohistochemistry. 
  • Available in Kras/p53 PDAC or Kras/p53 NSCLC mice. Additional information.

Serguei Kozlov, Ph.D.,
kozlovse@mail.nih.gov

 

LASP-06
LASP-07
LASP-10
LASP-11

 

Other Services

Service

Description

Contact

FNLCR Technical Service Number

Class I & II HLA 4-Digit Typing

Pat Martin, M.D.,
Maureen.Martin@nih.gov

BSP-01

mRNA Isolation and Expression Analysis in Human B-cell Lymphoma Samples

  • 20-gene panel to identify Activated B-cell (ABC) and Germinal Center B-cell (GCB) subtypes of Diffuse Large B-cell Lymphomas (DLBCL) using the NanoString platform under CLIA conditions in formalin-fixed paraffin-embedded (FFPE) samples. Additional information

Daniel Soppet, Ph.D.,
soppetdr@mail.nih.gov

 

CRTP-13
TypeSeqer HPV Genotyping Joe Boland,
bolandj2@mail.nih.gov
DCEG-CGR-01